Raju Prasad - 14 Mar 2025 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role: Chief Financial Officer
Signature: Elizabeth Ryland Waldinger, attorney-in-fact
Issuer symbol: CRSP
Transactions as of: 14 Mar 2025
Net transactions value: -$157,252
Form type: 4
Filing time: 18 Mar 2025, 17:35:07 UTC
Previous filing: 18 Oct 2024
Next filing: 24 Mar 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CRSP	Common Shares	Options Exercise		+10,000	+154%		16,476	14 Mar 2025	Direct	F1
transaction	CRSP	Common Shares	Sale	$157,252	-3,762	-23%	$41.80	12,714	17 Mar 2025	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CRSP	Restricted Stock Units	Options Exercise		-10,000	-33%		20,000	14 Mar 2025	Common Shares	10,000		Direct	F1, F3
transaction	CRSP	Stock Option (Right to Buy)	Award	$0	+36,666		$0.000000	36,666	14 Mar 2025	Common Shares	36,666	$42.12	Direct	F4
transaction	CRSP	Restricted Stock Units	Award	$0	+27,500		$0.000000	27,500	14 Mar 2025	Common Shares	27,500		Direct	F1, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F2	Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
F3	This restricted stock unit award was granted on March 14, 2023 with respect to 40,000 Common Shares, with (i) one quarter of the shares vesting on March 14, 2024, (ii) one quarter of the shares vesting on March 14, 2025, (iii) one quarter of the shares vesting on March 14, 2026, and (iv) one quarter of the shares vesting on March 14, 2027.
F4	This option was granted on March 14, 2025 with respect to 36,666 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 14, 2025.
F5	This restricted stock unit award was granted on March 14, 2025 with respect to 27,500 Common Shares, with (i) one quarter of the shares vesting on March 14, 2026, (ii) one quarter of the shares vesting on March 14, 2027, (iii) one quarter of the shares vesting on March 14, 2028, and (iv) one quarter of the shares vesting on March 14, 2029.